相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
Powder:2-8℃,2 years;Insolvent(母液):-20℃,6 months;-80℃,1 year
- 保质期:
Powder:2-8℃,2 years;Insolvent(母液):-20℃,6 months;-80℃,1 year
- 英文名:
Timosaponin BⅡ
- 库存:
现询
- 供应商:
北京索莱宝科技有限公司
- CAS号:
136656-07-0
- 规格:
100mg/50mg/25mg/1mg/10mg/5mg
| 规格: | 100mg | 产品价格: | ¥4904.0 |
|---|---|---|---|
| 规格: | 50mg | 产品价格: | ¥3354.0 |
| 规格: | 25mg | 产品价格: | ¥2228.0 |
| 规格: | 1mg | 产品价格: | ¥294.0 |
| 规格: | 10mg | 产品价格: | ¥1354.0 |
| 规格: | 5mg | 产品价格: | ¥870.0 |
Timosaponin BII 是一种抗氧化剂和抗炎化合物。
使用本产品的应用案例(仅供参考)
In Vitro
In Vitro Incubation of Timosaponin BII with Gut Microbiota
After 7 SD rats were sacrificed, the colon contents were collected and added to the sterilized anaerobic medium (Solarbio Life Sciences Co., Ltd., Beijing, China) at a ratio of 1.0 g:20 mL, and stirred gently. After filtering, the culture medium containing gut microbiota (mixed medium) was placed in a N2 atmosphere, and pre-incubated at 37 ?C for 60 min before use. Accurately weigh 1.0 mg of timosaponin BII and dissolve with methanol to obtain a solution of 1 mg/mL. The incubation system consists of 10 μL of timosaponin BII in methanol (1 mg/mL), and 990 μL of mixed medium. The incubation was conducted in a 37 ?C, 200 rpm shaking incubator. The incubation system must be maintained completed in an anaerobic environment during the experiment. In the first incubation experiment, the timosaponin BII and mixed medium were incubated for 0, 1, 2, 6, 12, and 24 h, respectively. In the second incubation experiment, the drugs and mixed medium were incubated for 0, 0.25, 0.5, 1, 1.5, and 2 h, respectively. In addition, the negative control group was introduced consisting of twice boiled mixed medium incubated with the same amount of timosaponin BII. The termination reaction was carried out by adding 3-fold volume of 100 ng/mL glipizide methanol solution (IS), shaking it evenly and then precipitating the protein. After each sample was centrifuged at 13,400× g rpm in a 4 ?C refrigerated centrifuge for 10 min, 10 μL of supernatant was injected for LC-MS/MS analysis, and 7 μL of supernatant was injected for LC/MS-Q-TOF analysis.
In Vitro Incubation of Timosaponin BII with Liver Microsomes and Liver Homogenate
The liver microsome incubation system was consisted of the following: 5 μL SD rat liver microsomes (20 mg/mL), 2 μL timosaponin BII (1 mM), 20 μL of NADPH, and 0.05 mM Tris/HCl (pH = 7.4), with a total volume of 200 μL. The incubation was conducted in a shaking incubator at 37 ?C and 800 rpm with supply of oxygen. After the incubation, 3-fold volume of glipizide methanol solution (IS, 100 ng/mL) was added to the incubation system and mixed to stop the reaction at 0, 0.25, 0.5, 1, 1, 5, and 2 h. After centrifugation at 13,400× g rpm in a refrigerated centrifuge at 4 ?C for 10 min, 10 μL of the supernatant was injected for LC-MS/MS analysis.
Liver homogenate was prepared by homogenizing freshly collected SD rat livers and adding ice-cold normal saline with weight/volume = 1:3. The liver homogenate incubation system was consisted as follows: 2 μL timosaponin BII (1 mM), 198 μL of freshly prepared liver homogenate, with a total volume of 200 μL.
Incubation was conducted in a shaking incubator at 37 ?C and 800 rpm with supply of oxygen. After the incubation, 3-fold volume of glipizide methanol solution (IS, 100 ng/mL) was added to the incubation system and mixed to stop the reaction at 0, 0.25, 0.5, 1, 1, 5, and 2 h. After centrifugation at 13,400× g rpm in a refrigerated centrifuge at 4 ?C for 10 min, 10 μL of the supernatant was injected for LC-MS/MS analysis.
来源文献:Dong GM, Yu H, Pan LB, Ma SR, Xu H, Zhang ZW, Han P, Fu J, Yang XY, Keranmu A, Niu HT, Jiang JD, Wang Y. Biotransformation of Timosaponin BII into Seven Characteristic Metabolites by the Gut Microbiota. Molecules. 2021 Jun 24;26(13):3861. doi: 10.3390/molecules26133861. PMID: 34202717; PMCID: PMC8270264.
【本资料源自公开渠道,如需(此处)屏蔽,请联系删除】
标题:Timosaponin B-II alleviates osteoarthritis-related inflammation and extracellular matrix degradation through inhibition of mitogen-activated protein kinases and nuclear factor-κB pathways in vitro
成员:Xinwei Liu, Dulei Xiang, Wenming Jin, Gen Zhao, Han Li, Bing Xie, Xiaochuan Gu
论文因子:6.832 发表期刊:Bioengineered pmid:35094658
【本资料源自公开渠道,如需(此处)屏蔽,请联系删除】
标题:Biotransformation of Timosaponin BII into Seven Characteristic Metabolites by the Gut Microbiota.
成员:Dong GM, Yu H, Pan LB, Ma SR, Xu H, Zhang ZW, Han
论文因子:4.148 发表期刊:Molecules. pmid:34202717
| 基本信息 | |
| CAS | No.136656-07-0 |
| 中文名称 | 知母皂苷BⅡ |
| 英文名称 | Timosaponin BⅡ |
| 别名 | ;知母皂苷B2;知母皂苷BII;知母皂苷BⅡ; |
| 分子式 | C45H76O19 |
| 分子量 | 921.07 |
| 溶解性 | Soluble in DMSO |
| 纯度 | HPLC≥98% |
| 外观(性状) | White to off-white Solid |
| 储存条件 | Powder:2-8℃,2 years;Insolvent(母液):-20℃,6 months;-80℃,1 year |
| MDL | MFCD30179489 |
| SMILES | C[C@@]1([C@]([C@@H]2C)([H])[C@](O[C@]2(O)CC[C@H](C)CO[C@@H]([C@@H]([C@@H](O)[C@@H]3O)O)O[C@@H]3CO)([H])C4)[C@]4([H])[C@@](CC[C@@]5([H])[C@@]6(CC[C@H](O[C@@](O[C@H](CO)[C@H](O)[C@@H]7O)([H])[C@@H]7O[C@]([C@@H]([C@@H](O)[C@@H]8O)O)([H])O[C@@H]8CO)C5)C)([H])[C@]6([H])CC1 |
| 靶点 | Others |
| 通路 | Others |
| 背景说明 | Timosaponin BII 是一种抗氧化剂和抗炎化合物。 |
| 生物活性 | Timosaponin BII 是一种抗氧化剂和抗炎化合物。[1-2] |
| In Vitro | Timosaponin BII是一种从Zhi Mu中分离出的甾体糖苷,被发现具有抑制HL-60(白血病),Hela(子宫颈),HepG2和Bel-7402(肝脏),HT-29(结肠)增殖的抑制活性,和MDA-MB-468(乳腺)人癌细胞系在HL-60细胞中的IC50值为15.5μg/ mL [1]。 |
| 细胞实验 | 模型组和载体对照组中的大鼠视网膜表现出BACE1表达的明显上调。同时,丙二醛(MDA),Aβ1-40和β-CTF的水平增加。然而,当与媒介物对照组相比时,Timosaponin-BII处理组中的视网膜显示出显著更少的BACE1并且累积更少的Aβ1-40或β-CTF。它还显示MDA水平显著降低和部分凝血活酶时间延长[2]。 |
| 数据来源文献 | [1]. Guo J, et al. Cytotoxic activities of chemical constituents from rhizomes of Anemarrhena asphodeloides and their analogues. Arch Pharm Res. 2015;38(5):598-603. [2]. Huang JF, et al. Timosaponin-BII inhibits the up-regulation of BACE1 induced by ferric chloride in rat retina. BMC Complement Altern Med. 2012 Oct 22;12:189. |
| 单位 | 瓶 |
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验【本资料源自公开渠道,如需(此处)屏蔽,请联系删除】
标题:Timosaponin B-II alleviates osteoarthritis-related inflammation and extracellular matrix degradation through inhibition of mitogen-activated protein kinases and nuclear factor-κB pathways in vitro
成员:Xinwei Liu, Dulei Xiang, Wenming Jin, Gen Zhao, Han Li, Bing Xie, Xiaochuan Gu
论文因子:6.832 发表期刊:Bioengineered pmid:35094658
【本资料源自公开渠道,如需(此处)屏蔽,请联系删除】
标题:Biotransformation of Timosaponin BII into Seven Characteristic Metabolites by the Gut Microbiota.
成员:Dong GM, Yu H, Pan LB, Ma SR, Xu H, Zhang ZW, Han
论文因子:4.148 发表期刊:Molecules. pmid:34202717
。染色体中的组蛋白去乙酰化可使染色体的结构更加致密,从而抑制基因的转录。组蛋白去乙酰化酶抑制剂使染色体由致密状态变为活化状态,从而使一些抑制肿瘤生长的基因激活。因此,这些抑制剂有望开发为肿瘤治疗的药物。组蛋白去乙酰化酶(HDAC)在哺乳动物中可分为3类。 (1)第一类:为酵母转录调控子 RPD3 蛋白的同类物,这是第一个被鉴定出来的 HDAC。它包括 HDACl~3,可与转录因子E2F 结合,通过与 Rb 蛋白相关途径抑制转录。 (2)第二类:为酵母 HDAl 类蛋白质,包括 HDAC4~
网络 幽门螺杆菌感染与十二肠溃疡的治疗 H 2 受体拮抗剂应用于临床以来,消化生溃疡的治疗取得了长足的进步,H + -K + -APT酶抑制剂洛赛克(Omeprazole)的问世,更使得一些所谓“顽固性”溃疡得以愈合。近年来幽门螺杆菌(Helicobacter pylori
,2F12;CRIS-3 Leu LFA-1(gp180/95)的α链 与ICAM-1(CD54)和ICAM-2(CD102)结合 CD11b Mol,OKM1; (Mac-1,CR3,integrin αm G,M,NK gp165/95的α链 C3bi和FB受体,与ICAM-1结合,粘附,调理吞噬 CD11c LeuM5;(CR4,integrin αx) M,G,NK,Tsub gp150/95的α链 C3bi受体,调理吞噬
技术资料暂无技术资料 索取技术资料










